New 1,3,4-thiadiazole derivatives as inhibitors of critical steps of the glutamine-glutamate cycle in glioblastoma cells.

2013/11/D/NZ7/00925

Keywords

Descriptors

  • NZ7_14: Farmacja, farmakoterapia, farmakologia

Panel

NZ7 – Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology

Host institution

Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

Voivodeship: mazowieckie

Other projects carried out by the institution »

Principal investigator (from the host institution)

dr hab. Monika Paulina Szeliga

Number of co-investigators in the project: 3

Call

SONATA 6 – announced on 2013-09-16

Amount awarded
435 500 PLN
Project start date
2014-07-10
Project end date
2018-01-09
Project duration
42 months (the same as in the proposal)
Project status
Project settled

Information in the final report

Publication in academic press/journals (2)

  1. Downregulation of GLS2 in glioblastoma cells is related to DNA hypermethylation but not to the p53 status.

    Authors:
    Szeliga M, Bogacińska-Karaś M, Kuźmicz K, Rola R, Albrecht J.
    Academic press:
    Molecular Carcinogenesis (year: 2016, volume: 55(9), pages: 1309-1316), Publisher: Wiley Periodicals, Inc.
    Status:
    Published
    DOI:
    10.1002/mc.22372 – link to the publication
  2. Transfection with GLS2 Glutaminase (GAB) Sensitizes Human Glioblastoma Cell Lines to Oxidative Stress by a Common Mechanism Involving Suppression of the PI3K/AKT Pathway.

    Authors:
    Majewska E, Márquez J, Albrecht J, Szeliga M.
    Academic press:
    Cansers (Basel) (year: 2019, volume: 11, pages: pii: E115), Publisher: MDPI
    Status:
    Published
    DOI:
    10.3390/cancers11010115. – link to the publication

« New search

Graphic design and implementation: Jakub Piotrowski